| Literature DB >> 31938730 |
Yoshiaki Yamanaka1, Kunitaka Menuki1, Yukichi Zenke1, Satoshi Ikeda2, Eiji Hatakeyama3, Kimiaki Kawano4, Satoshi Nishida5, Hiroaki Tanaka6, Keiichi Yumisashi7, Akinori Sakai1.
Abstract
OBJECTIVES: To assess the vitamin D status in postmenopausal women with osteoporotic fractures, determine its concentration by fracture site at the clinical setting, and compare the proportion of vitamin D deficiency with that reported in literature.Entities:
Keywords: 25-hydroxyvitamin D; Bone mineral density; Fracture; Osteoporosis; Postmenopausal women
Year: 2019 PMID: 31938730 PMCID: PMC6953523 DOI: 10.1016/j.afos.2019.11.002
Source DB: PubMed Journal: Osteoporos Sarcopenia ISSN: 2405-5255
Patient characteristics.
| Characteristic | All | Vertebral fracture | Hip fracture | Distal radius fracture | Proximal humeral fracture | P-value |
|---|---|---|---|---|---|---|
| Number of patients | 317 | 132 | 121 | 46 | 18 | |
| Age, yr | 80.7 ± 0.54 | 80.1 ± 0.84 | 83.9 ± 0.77 | 76.1 ± 1.50 | 75.6 ± 2.07 | <0.001 |
| Albumin, g/dL | 3.94 ± 0.26 | 3.36 ± 0.06 | 3.36 ± 0.06 | 4.04 ± 0.06 | 3.61 ± 0.08 | 0.34 |
| Albumin-corrected calcium, mg/dL | 9.19 ± 0.03 | 9.22 ± 0.04 | 9.21 ± 0.07 | 9.19 ± 0.09 | 9.17 ± 0.14 | 0.63 |
| Phosphate, mg/dL | 3.37 ± 0.04 | 3.43 ± 0.04 | 3.32 ± 0.07 | 3.32 ± 0.08 | 3.25 ± 0.17 | 0.48 |
| 25-hydroxyvitamin D, ng/mL | 17.3 ± 0.82 | 16.4 ± 1.07 | 17.1 ± 1.45 | 19.5 ± 2.34 | 20.3 ± 3.90 | 0.51 |
| Tartrate-resistant acid phosphatase 5b, mU/dL | 391 ± 12.2 | 345 ± 15.0 | 449 ± 23.4 | 398 ± 29.9 | 310 ± 34.1 | <0.001 |
| Undercarboxylated osteocalcin, ng/mL | 8.41 ± 1.84 | 9.25 ± 4.00 | 9.05 ± 1.98 | 5.49 ± 0.71 | 4.14 ± 1.02 | 0.87 |
| Lumbar spine BMD, g/cm2 | 0.74 ± 0.01 | 0.71 ± 0.01 | 0.74 ± 0.02 | 0.78 ± 0.02 | 0.78 ± 0.03 | 0.07 |
| Femoral neck BMD, g/cm2 | 0.49 ± 0.01 | 0.49 ± 0.01 | 0.46 ± 0.01 | 0.57 ± 0.02 | 0.54 ± 0.03 | <0.001 |
Values are presented as mean ± standard error.
BMD, bone mineral density.
Fig. 1Percentage of patients by serum 25-hydroxyvitamin D concentration in each osteoporotic fracture site.
Fig. 2Comparison of 25-hydroxyvitamin D (25(OH)D) serum concentrations in each osteoporotic fracture site in patients with 25(OH)D concentrations < 30 ng/mL (vitamin D insufficiency).
Simple linear regression analysis and multiple linear stepwise regression analysis (n = 317).
| Variable | 25-hydroxyvitamin D (ng/mL) | ||||
|---|---|---|---|---|---|
| Simple linear regression analysis | Multiple linear stepwise regression analysis | ||||
| R | P-value | β (95% CI) | t-value | P-value | |
| Age, yr | 0.00 | 0.50 | - | −0.10 | 0.92 |
| Lumbar spine BMD, g/cm2 | −0.04 | 0.30 | - | −0.53 | 0.60 |
| Femoral neck BMD, g/cm2 | −0.02 | 0.40 | - | −0.07 | 0.95 |
| Albumin, g/dL | 0.10 | 0.08 | - | 0.97 | 0.34 |
| Albumin-corrected calcium, mg/dL | −0.14 | 0.02 | −0.137 (−6.55 to −0.10) | −2.03 | 0.04 |
| Phosphate, mg/dL | −0.04 | 0.27 | - | −0.32 | 0.75 |
| Tartrate-resistant acid phosphatase 5b, mU/dL | 0.04 | 0.29 | - | 0.58 | 0.56 |
| Undercarboxylated osteocalcin, ng/mL | −0.09 | 0.10 | - | −1.15 | 0.25 |
| Existing fragility fracture | - | - | - | 0.06 | 0.96 |
| Vertebral fracture | - | - | - | −0.29 | 0.77 |
| Hip fracture | - | - | - | −0.96 | 0.34 |
| Distal radius fracture | - | - | - | 1.08 | 0.28 |
| Proximal humerus fracture | - | - | - | 0.97 | 0.33 |
| Home | - | - | - | −0.88 | 0.38 |
| Hospital | - | - | - | 0.56 | 0.57 |
| Facility | - | - | - | 0.67 | 0.51 |
R = correlation coefficient; β = standardized correlation coefficients (95% confidence interval [CI]); BMD, bone mineral density.
Simple linear regression analysis and multiple linear stepwise regression analysis (25-hydroxyvitamin D < 30 ng/mL) (n = 279).
| Variable | 25-hydroxyvitamin D (ng/mL) | ||||
|---|---|---|---|---|---|
| Simple linear regression analysis | Multiple linear stepwise regression analysis | ||||
| R | P-value | β (95% CI) | t-value | P-value | |
| Age, yr | −0.12 | 0.05 | - | 0.41 | 0.68 |
| Lumbar spine BMD, g/cm2 | 0.06 | 0.19 | - | −0.62 | 0.54 |
| Femoral neck BMD, g/cm2 | 0.20 | <0.001 | 0.16 (0.78–12.17) | 2.24 | 0.03 |
| Albumin, g/dL | 0.24 | <0.001 | 0.21 (0.62–2.96) | 3.01 | <0.001 |
| Albumin-corrected calcium, mg/dL | 0.04 | 0.29 | - | 1.21 | 0.23 |
| Phosphate, mg/dL | 0.07 | 0.15 | - | 0.98 | 0.33 |
| Tartrate-resistant acid phosphatase 5b, mU/dL | −0.15 | 0.02 | - | −1.37 | 0.17 |
| Undercarboxylated osteocalcin, ng/mL | −0.08 | 0.12 | - | −0.86 | 0.39 |
| Existing fragility fracture | - | - | - | −1.56 | 0.12 |
| Vertebral fracture | - | - | - | 1.57 | 0.12 |
| Hip fracture | - | - | - | −1.67 | 0.10 |
| Distal radius fracture | - | - | - | 0.17 | 0.87 |
| Proximal humerus fracture | - | - | - | −0.32 | 0.75 |
| Home | - | - | - | −0.27 | 0.79 |
| Hospital | - | - | - | −0.83 | 0.41 |
| Facility | - | - | - | 0.78 | 0.44 |
R = correlation coefficient; β = standardized correlation coefficients (95% confidence interval [CI]); BMD, bone mineral density.